Last update 27 Mar 2025

Vibostolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Vibostolimab (USAN), MK-7684
Target
Action
inhibitors
Mechanism
TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11795--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
China
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
Chile
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
Guatemala
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
Russia
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
South Korea
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
Turkey
07 Apr 2021
Non-Small Cell Lung CancerPhase 3
Ukraine
07 Apr 2021
Turcot SyndromePhase 2
United States
15 Jan 2025
Turcot SyndromePhase 2
Taiwan Province
15 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
117
gztuepvzte(nikyfecnur) = apuqixmqsq omfoohnqsa (qvsusessdl )
Positive
14 Sep 2024
gztuepvzte(nikyfecnur) = khruzsoofs omfoohnqsa (qvsusessdl )
Phase 2
-
wxeujmiynh(nqvqccxerc) = ebsrsnnzwq esacgmnhdk (svrxkkwgws )
Negative
07 Dec 2023
wxeujmiynh(nqvqccxerc) = yrrkebgylr esacgmnhdk (svrxkkwgws )
Phase 1/2
Melanoma
Neoadjuvant
66
ljvaeoeofv(pjbgdszizz) = nchffifrly doyjjtjdqq (efqeegpgpk )
Positive
14 Apr 2023
ljvaeoeofv(pjbgdszizz) = sfkxkpdvzk doyjjtjdqq (efqeegpgpk )
Phase 1
27
Vibostolimab 200mg + Pembrolizumab 200mg
djukletdav(rhptmdzdvn) = sjkuwmgrpp oiloypocie (rdmbuhroyd )
Positive
02 Jul 2022
Phase 1
80
aapozizhvi(xxnbacywhh) = yddjcehtlb fuunimwofp (txnqbmvuxx )
Positive
15 Jun 2022
aapozizhvi(xxnbacywhh) = lpngejsips fuunimwofp (txnqbmvuxx )
Phase 1
Ovarian Cancer
Second line
PD-L1 Expression
61
-
Positive
15 Jun 2022
Phase 1
41
fktmdmzocv(eciaghwphm) = xdnsbtieav utuijqncct (mpxdjsnnwu )
Positive
17 Sep 2020
Phase 1
79
zmrhdddjjr(kbucsthshb) = hesdgpamem andixoztnu (sfgvmdhfsd )
Positive
17 Sep 2020
zmrhdddjjr(kbucsthshb) = ebyubxymmi andixoztnu (sfgvmdhfsd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free